tbuckley/cabot-search huggingface dataset:
1032P Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumour entities
Authors: T.O. Goetze, D.W. Müller, M-R. Rafiyan, D. Kiselicki, T. Habibzade, R. Eickhoff, E. Jäger, S-E. Al-Batran
Journal: Annals of Oncology (2020)
819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Authors: G. Valabrega, B. Pothuri, A. Oaknin, W. Graybill, A.B. Sánchez, C. Mccormick, J-F. Baurain, P. Hoskins, H. Denys, R.E. O’Cearbhaill, S. Heitanen, R.G. Moore, A.Ø. Knudsen, T. de La Motte Rouge, F. Heitz, T. Levy, Y. Li, D. Gupta, B.J. Monk, A. González Martín
Journal: Annals of Oncology (2020)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas Antón, Edwin R Parra, Ignacio Wistuba, Virginia Calvo, Raquel Laza-Briviesca, Atocha Romero, Bartomeu Massuti, Alberto Cruz-Bermúdez
Journal: The Lancet Oncology (2020)
LBA87 A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)
Authors: M.K. Krzyzanowska, J. Julian, C-S. Gu, M. Powis, Q. Li, K.A. Enright, D. Howell, C. Earle, S. Gandhi, S. Rask, C. Brezden-Masley, S.F. Dent, L. Hajra, O. Freedman, S. Spadafora, C. Hamm, N. Califaretti, M. Trudeau, M. Levine, E. Grunfeld
Journal: Annals of Oncology (2020)
307P Real-world evidence of CDK4/6 Inhibitor combination effects on assessing outcome with different sequence of treatment among adult patients with HR + and HER2 - metastatic breast cancer
Authors: S. Comis, T. Kandasamy, C. Wu, S.P. Kumar, V.P. Upadhyay, A. Chhikara
Journal: Annals of Oncology (2020)
1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)
Authors: S. Ponce, K. Brendel, D.R. Spigel, Y. Chen, M. Jove Casulleras, O. Juan-Vidal, P. Rich, T. Hayes, V. Gutiérrez Calderón, R. Bernabe Caro, A. Navarro, A. Dowlati, B. Zhang, Y. Moore, J. Kokhreidze, A. Pedret-Dunn, L. Paz-Ares, P.A. Bunn
Journal: Annals of Oncology (2020)
1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)
Authors: S. Popat, O.T. Brustugun, J. Cadranel, E. Felip, M.C. Garassino, F. Griesinger, Å. Helland, M.J. Hochmair, M. Pérol, N. Bent-Ennakhil, C. Kruhl, S. Novello
Journal: Annals of Oncology (2020)
677P A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis
Authors: D. Kilari, J. Zittel, A. Patel, D. Sahasrabudhe, C. Feng, J. Burfeind, E. Guancial, E. Messing, K. Bylow, S. Mohile, C. Fung
Journal: Annals of Oncology (2020)
210P 2D-echocardiography strain vs. cardiac MRI strain using deep learning: A prospective cohort study in HER2-positive breast cancer patients undergoing trastuzumab treatment
Authors: N.I. Bouwer, M-D. Levin, M.J.M. Kofflard, J.J. Brugts, M.C.J. Kock, J. Kitzen, E. Boersma
Journal: Annals of Oncology (2020)
824P Real-world-data (RWD) on platinum (Pt) outcomes after PARP inhibitors (PARPi) progression in high grade serous ovarian cancer (HGSOC) patients (p)
Authors: A. Plaja Salarich, I. Teruel García, B. Pardo Burdalo, M. Gil-Martin, J.M. Piulats, C. Fina Planas, M.P. Barretina Ginesta, A. Ferrando Diez, L. Notario Rincon, A. Pous Badia, A. Gonzalez Valencia, A. Esteve Gomez, M. Romeo Marin
Journal: Annals of Oncology (2020)
A Novel <i>RELA</i> Truncating Mutation in a Familial Behçet’s Disease–like Mucocutaneous Ulcerative Condition
Authors: Fahd Adeeb, Emma R. Dorris, Niamh E. Morgan, Dylan Lawless, Aqeel Maqsood, Wan Lin Ng, Orla Killeen, Eoin P. Cummins, Cormac T. Taylor, Sinisa Savic, Anthony G. Wilson, Alexander Fraser
Journal: Arthritis & Rheumatology (2020)

Monogenic Behçet's disease (BD)-like conditions are increasingly recognized and to date have been found to predominantly involve loss-of-function variants in TNFAIP3. This study was undertaken to identify genetic and pathobiologic mechanisms associated with a BD-like mucocutaneous ulcerative syndrome and neuromyelitis optica (NMO) occurring in 3 generations of an Irish family (n = 5 cases and 5 familial controls).Whole-exome sequencing was used to identify potential pathogenic variants in affected family members and determine segregation between affected and unaffected individuals. Relative v-rel reticuloendotheliosis viral oncogene homolog A (RELA) expression in peripheral blood mononuclear cells was compared by Western blotting. Human epithelial and RelA-/- mouse fibroblast experimental systems were used to determine the molecular impact of the RELA truncation in response to tumor necrosis factor (TNF). NF-κB signaling, transcriptional activation, apoptosis, and cytokine production were compared between wild-type and truncated RELA in experimental systems and patient samples.A heterozygous cytosine deletion at position c.1459 in RELA was detected in affected family members. This mutation resulted in a frameshift p.His487ThrfsTer7, producing a truncated protein disrupting 2 transactivation domains. The truncated RELA protein lacks a full transactivation domain. The RELA protein variants were expressed at equal levels in peripheral mononuclear cells. RelA-/- mouse embryonic fibroblasts (MEFs) expressing recombinant human RELAp.His487ThrfsTer7 were compared to those expressing wild-type RELA; however, there was no difference in RELA nuclear translocation. In RelA-/- MEFs, expression of RELAp.His487ThrfsTer7 resulted in a 1.98-fold higher ratio of cleaved caspase 3 to caspase 3 induced by TNF compared to wild-type RELA (P = 0.036).Our data indicate that RELA loss-of-function mutations cause BD-like autoinflammation and NMO via impaired NF-κB signaling and increased apoptosis.
1832P Nutritional status assessment in patients followed for head and neck cancer
Authors: A. Gabsi, None N. Jbali, Y. Yahiaoui, F. Letaief-Ksontini, F. Mghirbi, None A. Mokrani, K. Meddeb, M. Ayadi, H. Rais, N. Chraiet, A. Mezlini
Journal: Annals of Oncology (2020)
1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial
Authors: C. Lepage, J.M. Phelip, A. Lièvre, K. Le Malicot, D. Tougeron, L. Dahan, C. Toumpanakis, F. Di Fiore, C. Lombard Bohas, I. Borbath, R. Coriat, M. Caulet, R. Guimbaud, C. Petorin, J.L. Legoux, J-Y. Scoazec, P. Michel, G. Cadiot, D. Smith, T. Walter
Journal: Annals of Oncology (2020)
360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
Authors: M. Weller, D. Gramatzki, J. Felsberg, B. Hentschel, M. Wolter, G. Schackert, M. Westphal, L. Regli, N. Thon, M. Tatagiba, W. Wick, U. Schlegel, D. Krex, P. Roth, E. Rushing, T. Pietsch, A. von Deimling, M. Sabel, M. Loeffler, G. Reifenberger
Journal: Annals of Oncology (2020)
1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
Authors: M.C. Garassino, X. Le, D.M. Kowalski, M.R. Migliorino, H. Senellart, J. Fuentes Pradera, R. Walling, T. Kato, M. Thomas, E.F. Smit, M. Gottfried, C. Britschgi, A. Johne, J. Scheele, R. Bruns, H. Vioix, B. Pfeiffer, P.K. Paik
Journal: Annals of Oncology (2020)
568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
Authors: I. Colombo, S. Genta, F. Martorana, M. Guidi, E.S.P. Samartzis, S. Brandt, S. Gaggetta, L. Moser, M.R. Pascale, T. Terrot, C. Sessa, A. Stathis
Journal: Annals of Oncology (2020)
Readiness for voice assistants to support healthcare delivery during a health crisis and pandemic
Authors: Emre Sezgin, Yungui Huang, Ujjwal Ramtekkar, Simon Lin
Journal: npj Digital Medicine (2020)

To prevent the spread of COVID-19 and to continue responding to healthcare needs, hospitals are rapidly adopting telehealth and other digital health tools to deliver care remotely. Intelligent conversational agents and virtual assistants, such as chatbots and voice assistants, have been utilized to augment health service capacity to screen symptoms, deliver healthcare information, and reduce exposure. In this commentary, we examined the state of voice assistants (e.g., Google Assistant, Apple Siri, Amazon Alexa) as an emerging tool for remote healthcare delivery service and discussed the readiness of the health system and technology providers to adapt voice assistants as an alternative healthcare delivery modality during a health crisis and pandemic.
1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
Authors: C. Jay, L. Stanbery, F. Kerneis, J. Nemunaitis, P. Aaron, L. Manning, G. Wallraven, D. Shanahan, Y. Shen, N. Senzer, E. Bognar
Journal: Annals of Oncology (2020)
Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype
Authors: Na Qin, Zijian Ma, Cheng Wang, Erbao Zhang, Yuancheng Li, Mingtao Huang, Congcong Chen, Chang Zhang, Jingyi Fan, Yayun Gu, Xianfeng Xu, Liu Yang, Xiaoxia Wei, Rong Yin, Yue Jiang, Juncheng Dai, Guangfu Jin, Lin Xu, Zhibin Hu, Hongbing Shen, Hongxia Ma
Journal: Theranostics (2020)

Rationale: As the transcriptional products of active enhancers, enhancer RNAs (eRNAs) are essential for the initiation of tumorigenesis. However, the landscape and functional characteristics of eRNAs in Chinese lung adenocarcinoma, and the clinical utility of eRNA-based molecular subtypes remain largely unknown. Methods: A genome-wide profiling of eRNAs was performed in 80 Chinese lung adenocarcinoma patients with RNA-seq data. Functional eRNAs and associated genes were identified between paired adenocarcinoma and adjacent samples. Unsupervised clustering of functional eRNAs was conducted and the associations with molecular characteristics and clinical outcomes were accessed by integrating whole-genome sequencing data and clinical data. Additionally, 481 lung adenocarcinoma patients were used for the validation based on The Cancer Genome Atlas (TCGA) dataset. Results: A total of 3297 eRNAs with sufficient expression were identified, which were globally upregulated in adenocarcinoma samples compared to matched-adjacent pairs (P = 7.61×10-3). Further analyses indicated that these upregulated eRNAs were correlated with copy number amplification (CNA) status (Cor = 0.22, P = 0.045), and eRNA-correlated genes were primarily involved in cell cycle and immune system-related pathways. Based on the co-expression analysis of eRNAs with protein-coding genes, we defined 188 functional eRNAs and their correlated genes were overrepresented in cancer driver genes (ER = 1.98, P = 5.95×10-12) and clinically-actionable genes (ER = 2.19, P = 3.44×10-4). The eRNA-based consensus clustering further identified a novel molecular subtype with immune deficiency and a high-level of genomic alterations, which was associated with poor clinical outcomes of lung adenocarcinoma patients (OS: HR = 1.91, P = 0.015; PFI: HR = 1.64, P = 0.034). Conclusions: The genome-wide identification and characterization of eRNAs reveal novel regulators for the development of lung cancer, which provides a new biological dimension for the understanding of eRNAs during lung carcinogenesis and emphasize the clinical utility of eRNA-based molecular subtypes in the treatment of lung adenocarcinoma.
765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data
Authors: T. Elumalai, C. Aversa, B. Buijtenhuijs, R. Conroy, W. Croxford, A. Das, G. Doss, D. Enting, E. Kitetere, B. Sanderson, N. Vasudev, H. Mistry, A. Choudhury
Journal: Annals of Oncology (2020)
1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
Authors: M. Majem, E. Felip, B. Doger, M. Akay, E. Carcereny, T. Clay, M.G. Krebs, J. Peguero, F. Triebel
Journal: Annals of Oncology (2020)
1785P Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small cell lung cancer
Authors: B.T. Li, E.P. Hamilton, J.S. Wang, G.S. Falchook, A.M. Oza, E. Rodrigo Imedio, S. Kumar, G.M. Mugundu, E. De Bruin, D.R. Spigel, S. Fu
Journal: Annals of Oncology (2020)
1841P Predicting the onset of immune-related adverse events (irAEs) in immune checkpoint inhibitor (ICI) therapies using a machine learning (ML) model trained with electronic patient-reported outcomes (ePROs) and lab measurements
Authors: S.M.E. Iivanainen, J. Ekstrom, V. Kataja, H. Virtanen, J. Koivunen
Journal: Annals of Oncology (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Authors: Christopher P. Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino, Weichung J. Shih, Ira Gantz, Steven G. Terra, David Z.I. Cherney, Darren K. McGuire
Journal: New England Journal of Medicine (2020)

The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Small molecules regulating reactive oxygen species homeostasis for cancer therapy
Authors: Junmin Zhang, Dongzhu Duan, Zi‐Long Song, Tianyu Liu, Yanan Hou, Jianguo Fang
Journal: Medicinal Research Reviews (2020)

Elevated intracellular reactive oxygen species (ROS) and antioxidant defense systems have been recognized as one of the hallmarks of cancer cells. Compared with normal cells, cancer cells exhibit increased ROS to maintain their malignant phenotypes and are more dependent on the "redox adaptation" mechanism. Thus, there are two apparently contradictory but virtually complementary therapeutic strategies for the regulation of ROS to prevent or treat cancer. The first strategy, that is, chemoprevention, is to prevent or reduce intracellular ROS either by suppressing ROS production pathways or by employing antioxidants to enhance ROS clearance, which protects normal cells from malignant transformation and inhibits the early stage of tumorigenesis. The second strategy is the ROS-mediated anticancer therapy, which stimulates intracellular ROS to a toxicity threshold to activate ROS-induced cell death pathways. Therefore, targeting the regulation of intracellular ROS-related pathways by small-molecule candidates is considered to be a promising treatment for tumors. We herein first briefly introduce the source and regulation of ROS, and then focus on small molecules that regulate ROS-related pathways and show efficacy in cancer therapy from the perspective of pharmacophores. Finally, we discuss several challenges in developing cancer therapeutic agents based on ROS regulation and propose the direction of future development.
926P Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Authors: C. Fu-Ming, C-Y. Hsieh, T-H. Wang, M-H. Tsai, C-H. Hua, C-H. Tang, C-H. Hsieh, M-Y. Lien
Journal: Annals of Oncology (2020)
ROS production and mitochondrial dysfunction driven by PU.1-regulated NOX4-p22<sup>phox</sup> activation in Aβ-induced retinal pigment epithelial cell injury
Authors: Junran Sun, Jieqiong Chen, Tong Li, Peirong Huang, Jie Li, Mengxi Shen, Min Gao, Yang Sun, Jian Liang, Xiaomeng Li, Yimin Wang, Yushu Xiao, Xiang Shi, Yifan Hu, Jingyang Feng, Huixun Jia, Te Liu, Xiaodong Sun
Journal: Theranostics (2020)

Rationale: Amyloid β (Aβ) deposition, an essential pathological process in age-related macular degeneration (AMD), causes retinal pigment epithelium (RPE) degeneration driven mostly by oxidative stress. However, despite intense investigations, the extent to which overoxidation contributes to Aβ-mediated RPE damage and its potential mechanism has not been fully elucidated. Methods: We performed tandem mass-tagged (TMT) mass spectrometry (MS) and bioinformatic analysis of the RPE-choroid complex in an Aβ1-40-induced mouse model of retinal degeneration to obtain a comprehensive proteomic profile. Key regulators in this model were confirmed by reactive oxygen species (ROS) detection, mitochondrial ROS assay, oxygen consumption rate (OCR) measurement, gene knockout experiment, chromatin immunoprecipitation (ChIP), and luciferase assay. Results: A total of 4243 proteins were identified, 1069 of which were significantly affected by Aβ1-40 and found to be enriched in oxidation-related pathways by bioinformatic analysis. Moreover, NADPH oxidases were identified as hub proteins in Aβ1-40-mediated oxidative stress, as evidenced by mitochondrial dysfunction and reactive oxygen species overproduction. By motif and binding site analyses, we found that the transcription factor PU.1/Spi1 acted as a master regulator of the activation of NADPH oxidases, especially the NOX4-p22phox complex. Also, PU.1 silencing impeded RPE oxidative stress and mitochondrial dysfunction and rescued the retinal structure and function. Conclusion: Our study suggests that PU.1 is a novel therapeutic target for AMD, and the regulation of PU.1 expression represents a potentially novel approach against excessive oxidative stress in Aβ-driven RPE injury.
1773P Mainstreamed genetic testing for French breast and ovarian cancer patients and its utility during the COVID-19 pandemic
Authors: P.R. Benusiglio, C. Korenbaum, J. Ezenfis, S. Geoffron, C. Paul, S. Richard, V. Byrde, E. Guillerm, N. Basset, J-P. Lotz, N. Chabbert-Buffet, J. Gligorov, F. Coulet
Journal: Annals of Oncology (2020)
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Authors: F. Barata, H. Queiroga, E. Teixeira, T. Almodovar, M. Soares, B. Parente, J.C. Mellidez, P. Alves, A. Antunes
Journal: Pulmonology (2020)
1318P Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Authors: C. Dellepiane, S. Coco, M.G. Dal Bello, G. Rossi, E. Rijavec, F. Biello, M. Tagliamento, L. Longo, M. Mora, G. Anselmi, A. Alama, E. Bennicelli, F. Grossi, L. Zullo, K. Beshiri, A. Bottini, P. Pronzato, C. Genova
Journal: Annals of Oncology (2020)